Amphotericin B inhalation

Drug Profile

Amphotericin B inhalation

Alternative Names: ABIP; Amphotericin B inhalation powder; NKTR-024

Latest Information Update: 16 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nektar Therapeutics
  • Class Antifungals; Antiprotozoals; Macrolides
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Aspergillosis

Highest Development Phases

  • No development reported Aspergillosis

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 16 Jul 2010 No development reported - Phase-I for Aspergillosis in USA (Inhalation)
  • 31 Dec 2008 Novartis acquires amphotericin B programme
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top